Quick Answer
Sionna Therapeutics, Inc. reported Diluted EPS of $1.88 per share (loss) for fiscal year 2025.
Sionna Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.88 | +88.2% |
| 2024 | -$15.99 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.46 | +91.9% | +99.9% |
| June 30, 2025 | -$410.00 | +84.9% | +33.9% |
| March 31, 2025 | -$620.00 | +83.9% | -10834.7% |
| September 30, 2024 | -$5.67 | — | +99.8% |
| June 30, 2024 | -$2710.00 | — | +29.4% |
| March 31, 2024 | -$3840.00 | — | — |
- Sionna Therapeutics, Inc. showed an increase of +88.2% in Diluted EPS compared to the prior fiscal year.
- Over the 2024–2025 period, Sionna Therapeutics, Inc.’s diluted eps has grown by 88.2% (from $15.99 per share (loss) to $1.88 per share (loss)).
- The most recent figure is from Sionna Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: